Bioray Biotech Co (ROCO:7561) Piotroski F-Score: 9 (As of Jul. 03, 2026) — 80% Above Median


ROCO:7561 Bioray Biotech Co Ltd ROCO:7561
83 GF Score
Price NT$18.05
GF Value NT$29.48
Valuation Significantly Undervalued
View Full Analysis

What is Bioray Biotech Co Piotroski F-Score?

Bioray Biotech Co ROCO:7561 83 Piotroski F-Score is 9 as of Jul. 03, 2026, which is 80% above its 10-year median of 5.00. GuruFocus rates ROCO:7561 with a GF Score™ of 83/100 and a GF Value™ of NT$29.48 (Significantly Undervalued). Among 981 Drug Manufacturers companies, Bioray Biotech Co ranks better than 99.9% on this metric.

Good Sign:

Piotroski F-Score is 9, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bioray Biotech Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Bioray Biotech Co's Piotroski F-Score or its related term are showing as below:

ROCO:7561' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 9
Current: 9

During the past 9 years, the highest Piotroski F-Score of Bioray Biotech Co was 9. The lowest was 3. And the median was 5.

Bioray Biotech Co  (ROCO:7561) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Bioray Biotech Co Piotroski F-Score Related Terms


Bioray Biotech Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Bioray Biotech Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioray Biotech Co Piotroski F-Score Chart

Bioray Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 5.00 6.00 3.00 7.00 9.00

Bioray Biotech Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 0.00 7.00 0.00 9.00

ROCO:7561 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioray Biotech Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Bioray Biotech Co's Piotroski F-Score falls into.


ROCO:7561
83GF Score
Bioray Biotech Co Ltd ROCO:7561
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was NT$32.3 Mil.
Cash Flow from Operations was NT$71.6 Mil.
Revenue was NT$222.7 Mil.
Gross Profit was NT$105.9 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (543.634 + 536.582) / 2 = NT$540.108 Mil.
Total Assets at the begining of this year (Dec24) was NT$543.6 Mil.
Long-Term Debt & Capital Lease Obligation was NT$42.8 Mil.
Total Current Assets was NT$319.7 Mil.
Total Current Liabilities was NT$40.7 Mil.
Net Income was NT$1.0 Mil.

Revenue was NT$201.7 Mil.
Gross Profit was NT$79.0 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (542.648 + 543.634) / 2 = NT$543.141 Mil.
Total Assets at the begining of last year (Dec23) was NT$542.6 Mil.
Long-Term Debt & Capital Lease Obligation was NT$79.1 Mil.
Total Current Assets was NT$305.4 Mil.
Total Current Liabilities was NT$43.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bioray Biotech Co's current Net Income (TTM) was 32.3. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bioray Biotech Co's current Cash Flow from Operations (TTM) was 71.6. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=32.25/543.634
=0.059323

ROA (Last Year)=Net Income/Total Assets (Dec23)
=1.002/542.648
=0.0018465

Bioray Biotech Co's return on assets of this year was 0.059323. Bioray Biotech Co's return on assets of last year was 0.0018465. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Bioray Biotech Co's current Net Income (TTM) was 32.3. Bioray Biotech Co's current Cash Flow from Operations (TTM) was 71.6. ==> 71.6 > 32.3 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=42.833/540.108
=0.07930451

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=79.126/543.141
=0.14568224

Bioray Biotech Co's gearing of this year was 0.07930451. Bioray Biotech Co's gearing of last year was 0.14568224. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=319.676/40.737
=7.84731325

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=305.385/43.727
=6.98390011

Bioray Biotech Co's current ratio of this year was 7.84731325. Bioray Biotech Co's current ratio of last year was 6.98390011. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Bioray Biotech Co's number of shares in issue this year was 29.606. Bioray Biotech Co's number of shares in issue last year was 29.834. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=105.935/222.725
=0.47563138

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=79.025/201.712
=0.39177144

Bioray Biotech Co's gross margin of this year was 0.47563138. Bioray Biotech Co's gross margin of last year was 0.39177144. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=222.725/543.634
=0.4096966

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=201.712/542.648
=0.37171795

Bioray Biotech Co's asset turnover of this year was 0.4096966. Bioray Biotech Co's asset turnover of last year was 0.37171795. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+1+1
=9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bioray Biotech Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 9 mean?
Bioray Biotech Co (ROCO:7561) has a Piotroski F-Score of 9 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bioray Biotech Co and its competitors. This is 80% above median its historical median of 5.00. Over the past decade, Bioray Biotech Co's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Bioray Biotech Co ranks #1 out of 981 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Bioray Biotech Co's Piotroski F-Score too high?
Bioray Biotech Co's current Piotroski F-Score of 9 is 80% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Bioray Biotech Co's value of 9 is 80% above this industry median. Based on the distribution chart, Bioray Biotech Co ranks #1 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bioray Biotech Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #1 out of 981 companies for Piotroski F-Score. This places Bioray Biotech Co in the top 0% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Bioray Biotech Co's value of 9 is 80% above this benchmark. Historically, Bioray Biotech Co's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Bioray Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current Piotroski F-Score of 9 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bioray Biotech Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current Piotroski F-Score is 9, which is 80% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.48, compared to a current price of NT$18.05 — trading 38.8% below its estimated fair value. The current Piotroski F-Score is 9, which is 80% above median its 10-year median of 5.00 and 80% above the Drug Manufacturers industry median of 5.00. Bioray Biotech Co's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current Piotroski F-Score is 9 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?

Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued. The current stock price of NT$18.05 is trading 38.8% below its estimated GF Value™ of NT$29.48. GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.

Key valuation signals for ROCO:7561:

  • Piotroski F-Score: 9 (80% above median its 10-year median of 5.00)
  • GF Value™: NT$29.48 vs. price of NT$18.05 (38.8% below fair value)
  • GF Score™: 83/100
  • Industry Position: 80% above the Drug Manufacturers median (#1 of 981)

No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioray Biotech Co Business Description

Address No. 1, Dali 2nd Road, Southern Science Park, Shanhua District, Tainan, TWN, 90846
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
83GF Score

Get the complete analysis for ROCO:7561

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.05
Price
NT$29.48
GF Value